Dose modulation: A new concept of antibiotic therapy in the critically ill patient?

Journal of Critical Care

Volumn 28, Issue 4, 2013, Pages 341-346

  Goncalves Pereira, Joao ^a   Paiva, José Artur ^b  

^a HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Antibiotics; Dose; Intensive care unit; Modulation; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; SEPSIS; SEPTIC SHOCK; STEADY STATE; CRITICAL ILLNESS; CROSS INFECTION; DOSE; INTENSIVE CARE UNIT; MICROBIOLOGY; MODULATION; PHARMACOKINETICS; TREATMENT OUTCOME;

ANTIBIOTICS; DOSE; INTENSIVE CARE UNIT; MODULATION; PHARMACOKINETICS;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMANS; INTENSIVE CARE UNITS; SEPSIS; TREATMENT OUTCOME;

EID: 84886656109     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.11.018     Document Type: Article

References (51)

1. Kumar A., Safdar N., Kethireddy S., et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010, 38:1651-1664.
2. Sandiumenge A., Diaz E., Bodi M., et al. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 2003, 29:876-883.
3. Eachempati S.R., Hydo L.J., Shou J., et al. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?. J Trauma 2009, 66:1343-1348.
4. Pea F., Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock-does the dose matter?. Crit Care 2009, 13:214.
5. Roberts J.A., Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45:755-773.
6. Lipman J., Wallis S.C., Boots R.J. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003, 97:1149-1154.
7. Rea R.S., Capitano B., Bies R., et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008, 30:674-681.
8. Roberts J.A., Taccone F.S., Udy A.A., et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011, 55:2704-2709.
9. Goncalves-Pereira J., Martins A., Povoa P. Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect 2010, 16:1258-1263.
10. Ulldemolins M., Roberts J.A., Lipman J., et al. Antibiotic dosing in multiple organ dysfunction syndrome. Chest 2011, 139:1210-1220.
11. Baptista J.P., Udy A.A., Sousa E., et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011, 15:R139.
12. Belzberg H., Zhu J., Cornwell E.E., et al. Imipenem levels are not predictable in the critically ill patient. J Trauma 2004, 56:111-117.
13. Taccone F.S., Laterre P.F., Dugernier T., et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126.
14. Baptista J.P., Sousa E., Martins P.J., et al. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents 2012, 39:420-423.
15. Udy A.A., Varghese J.M., Altukroni M., et al. Sub-therapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012, 142:30-39.
16. Roberts J.A., Ulldemolins M., Roberts M.S., et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36:332-339.
17. Thomson K.S., Moland E.S. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001, 45:3548-3554.
18. Paterson D.L., Ko W.C., Von Gottberg A., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004, 39:31-37.
19. Lisboa T., Seligman R., Diaz E., et al. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Crit Care Med 2008, 36:166-171.
20. Novotny A.R., Emmanuel K., Hueser N., et al. Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis. Surgery 2009, 145:20-26.
21. Nicasio A.M., Ariano R.E., Zelenitsky S.A., et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009, 53:1476-1481.
22. McKinnon P.S., Paladino J.A., Schentag J.J. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351.
23. Ariano R.E., Nyhlen A., Donnelly J.P., et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005, 39:32-38.
24. Taccone F.S., Laterre P.F., Spapen H., et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010, 14:R53.
25. Layeux B., Taccone F.S., Fagnoul D., et al. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010, 54:4939-4941.
26. Hafiz A.A., Staatz C.E., Kirkpatrick C.M., et al. Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. Minerva Anestesiol 2012, 78:94-104.
27. Nicasio A.M., Eagye K.J., Nicolau D.P., et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010, 25:69-77.
28. Triginer C., Izquierdo I., Fernandez R., et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990, 16:303-306.
29. Heinemeyer G., Link J., Weber W., et al. Clearance of ceftriaxone in critical care patients with acute renal failure. Intensive Care Med 1990, 16:448-453.
30. Pea F., Bertolissi M., Di Silvestre A., et al. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents 2002, 20:326-332.
31. Goncalves-Pereira J., Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011, 15:R206.
32. Aubert G., Carricajo A., Coudrot M., et al. Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit 2010, 32:517-519.
33. Chapuis T.M., Giannoni E., Majcherczyk P.A., et al. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14:R51.
34. Chatellier D., Jourdain M., Mangalaboyi J., et al. Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 2002, 28:214-217.
35. Lamoth F., Buclin T., Pascual A., et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 2010, 54:4360-4367.
36. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
37. Singer M., Glynne P. Treating critical illness: the importance of first doing no harm. PLoS Med 2005, 2:e167.
38. Soriano A., Miro O., Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005, 353:2305-2306.
39. Nicolau D.P., Freeman C.D., Belliveau P.P., et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995, 39:650-655.
40. Moise-Broder P.A., Forrest A., Birmingham M.C., et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942.
41. Jeurissen A., Rutsaert R. beta-Lactam antibiotics in continuous infusion in critically ill patients. Crit Care 2006, 14:446.
42. Niederman M.S. De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Care 2006, 12:452-457.
43. Court O., Kumar A., Parrillo J.E. Clinical review: myocardial depression in sepsis and septic shock. Crit Care 2002, 6:500-508.
44. Riou M., Carbonnelle S., Avrain L., et al. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 2010, 36:513-522.
45. Burgess D.S. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999, 115:19S-23S.
46. Tam V.H., Louie A., Fritsche T.R., et al. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 2007, 195:1818-1827.
47. Drusano G.L., Liu W., Brown D.L., et al. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J Infect Dis 2009, 199:219-226.
48. Tam V.H., Schilling A.N., Neshat S., et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49:4920-4927.
49. Micek S.T., Ward S., Fraser V.J., et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125:1791-1799.
50. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
51. Havey T.C., Fowler R.A., Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 2011, 15:R267.